Tran Nguyen Sells 10,000 Shares of Prothena Co. plc (NASDAQ:PRTA) Stock

Prothena Co. plc (NASDAQ:PRTAGet Rating) CFO Tran Nguyen sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $55.53, for a total value of $555,300.00. Following the sale, the chief financial officer now owns 3,200 shares of the company’s stock, valued at approximately $177,696. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Tran Nguyen also recently made the following trade(s):

  • On Wednesday, December 21st, Tran Nguyen sold 10,000 shares of Prothena stock. The stock was sold at an average price of $58.97, for a total value of $589,700.00.
  • On Wednesday, November 23rd, Tran Nguyen sold 10,000 shares of Prothena stock. The stock was sold at an average price of $61.09, for a total value of $610,900.00.

Prothena Stock Performance

Prothena stock opened at $54.56 on Friday. The firm has a market capitalization of $2.64 billion, a price-to-earnings ratio of -16.34 and a beta of 0.52. Prothena Co. plc has a fifty-two week low of $21.06 and a fifty-two week high of $66.47. The stock’s fifty day moving average is $58.16 and its two-hundred day moving average is $46.34.

Prothena (NASDAQ:PRTAGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.66). The company had revenue of $1.52 million for the quarter, compared to analyst estimates of $26.74 million. Prothena had a negative net margin of 3,036.03% and a negative return on equity of 36.46%. As a group, sell-side analysts forecast that Prothena Co. plc will post -2.86 EPS for the current fiscal year.

Institutional Trading of Prothena

A number of large investors have recently made changes to their positions in the stock. ProShare Advisors LLC boosted its stake in shares of Prothena by 3.0% during the third quarter. ProShare Advisors LLC now owns 7,858 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 228 shares during the last quarter. Credit Suisse AG boosted its stake in shares of Prothena by 1.3% during the second quarter. Credit Suisse AG now owns 27,724 shares of the biotechnology company’s stock valued at $753,000 after acquiring an additional 369 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Prothena during the third quarter valued at $27,000. Lazard Asset Management LLC boosted its stake in shares of Prothena by 61.1% during the first quarter. Lazard Asset Management LLC now owns 1,733 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 657 shares during the last quarter. Finally, Virtus ETF Advisers LLC lifted its position in Prothena by 22.7% during the second quarter. Virtus ETF Advisers LLC now owns 4,523 shares of the biotechnology company’s stock worth $123,000 after buying an additional 837 shares during the period. Institutional investors and hedge funds own 91.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PRTA shares. Royal Bank of Canada cut Prothena from an “outperform” rating to a “sector perform” rating and increased their price objective for the stock from $52.00 to $55.00 in a research report on Friday, November 4th. They noted that the move was a valuation call. Citigroup increased their price objective on Prothena from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Monday, October 24th. Bank of America upgraded Prothena from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $45.00 to $65.00 in a research report on Wednesday, September 28th. JMP Securities increased their price objective on Prothena from $50.00 to $81.00 in a research report on Wednesday, September 28th. Finally, TheStreet cut Prothena from a “c-” rating to a “d” rating in a research report on Friday, November 11th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $81.67.

Prothena Company Profile

(Get Rating)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Further Reading

Insider Buying and Selling by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.